{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:52:17Z","timestamp":1787849537495,"version":"build-2784847793"},"reference-count":17,"publisher":"Japan Atherosclerosis Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2020,5,1]]},"DOI":"10.5551\/jat.50963","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T22:03:56Z","timestamp":1574287436000},"page":"471-484","source":"Crossref","is-referenced-by-count":24,"title":["Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial"],"prefix":"10.5551","volume":"27","author":[{"given":"Shinji","family":"Koba","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Showa University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcoli","family":"Cyrille","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Lu","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoe","family":"Inomata","sequence":"additional","affiliation":[{"name":"Amgen Astellas BioPharma K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Shimauchi","sequence":"additional","affiliation":[{"name":"Amgen Astellas BioPharma K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Kajinami","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bruckert E, Hayem G, Dejager S, Yau C and B\u00e9gaud B: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther, 2005; 19: 403-414","DOI":"10.1007\/s10557-005-5686-z"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nagar SP, Rane PP, Fox KM, Meyers J, Davis K, Beaubrun A, Inomata H, Qian Y and Kajinami K: Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy. Circ J, 2018; 82: 1008-1016","DOI":"10.1253\/circj.CJ-17-0811"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Riaz H, Khan AR, Khan MS, Rehman KA, Alansari SAR, Gheyath B, Raza S, Barakat A, Luni FK, Ahmed H and Krasuski RA: Meta-analysis of placebo-controlled randomized controlled trials on the prevalence of statin intolerance. Am J Cardiol, 2017; 120: 774-781","DOI":"10.1016\/j.amjcard.2017.05.046"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN and Chilcott J: Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med, 2009; 265: 568-580","DOI":"10.1111\/j.1365-2796.2008.02062.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM and Stein EA: Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA, 2012; 308: 2497-2506","DOI":"10.1001\/jama.2012.25790"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM and Rocco M: Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebocontrolled phase 3 clinical trial of evolocumab. J Am Coll Cardiol, 2014; 63: 2541-2548","DOI":"10.1016\/j.jacc.2014.03.019"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R and Stein EA: Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA, 2016; 315: 1580-1590","DOI":"10.1001\/jama.2016.3608"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR and FOURIER Steering Committee Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM and Teramoto T: Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. Circ J, 2014; 78: 1073-1082","DOI":"10.1253\/circj.CJ-14-0130"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM and Hirayama A: A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. Am J Cardiol, 2016; 117: 40-47","DOI":"10.1016\/j.amjcard.2015.10.021"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Hirayama A, Yamashita S, Inomata H, Kassahun H, Cyrille M, Ruzza A, Yoshida M, Kiyosue A, Ma Y and Teramoto T: One-year efficacy and safety of evolocumab in Japanese patients- a pooled analysis from the openlabel extension OSLER studies. Circ J, 2017; 81: 1029-1035","DOI":"10.1253\/circj.CJ-16-1016"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K and Japan Atherosclerosis Society: Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb, 2013; 20: 517-523","DOI":"10.5551\/jat.15792"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Cho L, Dent R, Stroes ESG, Stein EA, Sullivan D, Ruzza A, Flower A, Somaratne R and Rosenson RS: Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cardiovasc Drugs Ther, 2018; 32: 365-372","DOI":"10.1007\/s10557-018-6817-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DA and Investigators OA: Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol, 2015; 9: 758-769","DOI":"10.1016\/j.jacl.2015.08.006"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Davidson ER, Snider MJ, Bartsch K, Hirsch A, Li J and Larry J: Tolerance of proprotein convertase subtilisin\/ kexin type 9 (PCSK9) inhibitors in patients with self-reported statin intolerance. J Pharm Pract, 2018; doi: 897190018799218","DOI":"10.1177\/0897190018799218"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Alonso R, Cuevas A and Cafferata A: Diagnosis and Management of Statin Intolerance. J Atheroscler Thromb, 2019; 26: 207-215","DOI":"10.5551\/jat.RV17030"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S, Committee for E and Clinical Management of A: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984","DOI":"10.5551\/jat.GL2017"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/27\/5\/27_50963\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T07:04:15Z","timestamp":1588835055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/27\/5\/27_50963\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.50963","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}